Calanus Oil Supplementation and Maximal Oxygen Uptake

Norwegian University of Science and Technology

Status: Completed

Conditions: Healthy

Treatments: Dietary Supplement: placebo dietary oil; Dietary Supplement: Calanus oil

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT02908828

2015/2303

Details and patient eligibility

About

Copepod oil is extracted from the marine copepod Calanus finmarchicus, the dominant plankton species in the marine food web in the Norwegian Sea. Copepods constitute the largest renewable and harvestable resource in the Norwegian Sea and adjacent waters, and it is now developed knowledge and technology for sustainable harvesting of this "new" resource. The purpose of this study is to investigate whether Calanus copepod oil supplementation has an equivalent effect on maximal oxygen uptake in humans to that seen in experimental studies in mice.

Enrollment: 71 patients

Sex: All

Ages: 30 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• in good health
• Body mass index (BMI) between 18,5 and 29,9

Exclusion criteria

• Medical condition limiting VO2max (COPD or asthma).
• diagnosed coronary artery disease
• Any other significant medical condition
• medication effecting exercise capacity (e.i. betablockers)
• Pregnancy
• Participation in other clinical trials
• Shellfish allergies
• Systolic blood pressure > 170 mmHG, or diastolic BP > 105 mmHG.
• contraindications for maximal exercise testing

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

71 participants in 2 patient groups, including a placebo group

Calanus oil

Experimental group

Description:

4 capsules of 500 mg Calanus oil once every day

Treatment:

Dietary Supplement: Calanus oil

Placebo

Placebo Comparator group

Description:

4 capsules of 500 mg dietary oil once every day

Treatment:

Dietary Supplement: placebo dietary oil